Clinical Pharmacology & Therapeutics
November 1, 1968
Leo E. Hollister, R. K. Richards, H. K. Gillespie
195 citations
A synthetic isomer of tetrahydrocannabinol (THC) was compared to a semisynthetic THC-like compound, synhexyl, in 16 volunteers. THC doses ranged from 341 to 946 µg per kilogram (median 581), while synhexyl doses ranged from 633 to 2,666 µg per kilogram (median 1,370). The clinical syndromes produced by the two drugs were similar, though synhexyl had a slower onset and was only about one third as potent. At higher doses, effects resembled those of psychotomimetics like LSD, but differed in that sedation was prominent, euphoria lasted longer, dreamlike sequences were more pronounced, and there were no sympathomimetic effects.
Science
November 3, 1967
Solomon H. Snyder, Louis A. Faillace, Leo E. Hollister
146 citations
In two independent trials with normal volunteers, 2,5-dimethoxy-4-methyl-amphetamine (the active chemical in the hallucinogenic drug STP) produced mild euphoria at low doses. Doses above 3 milligrams caused pronounced hallucinogenic effects lasting about 8 hours, similar to those from hallucinogenic doses of lysergic acid diethylamide, mescaline, and psilocybin. The compound is chemically related to both mescaline and amphetamine, about 100 times more potent as a hallucinogen than mescaline, and only one-thirtieth as potent as lysergic acid diethylamide. Chlorpromazine did not accentuate its psychological effects.
American Journal of Psychiatry
April 1, 1969
Leo E. Hollister, Jack Shelton, George Krieger
104 citations
In a controlled comparison of LSD and dextroamphetamine as treatments for alcoholism, seventy-two patients received either drug with minimal psychotherapeutic support. LSD showed slightly better outcomes early on, but after six months both groups had similar results. The authors argue that controlled studies are necessary to avoid mistakenly attributing special therapeutic powers to a particular treatment.
Psychopharmacology
January 1, 1963
Alan M. Hartman, Leo E. Hollister
77 citations
Psilocybin and other psychedelics like lysergic acid diethylamide and mescaline significantly enhance visual perception. In a study involving 120 participants, those under the influence reported a 75% increase in color vividness and improved hue discrimination. Participants also experienced heightened sensitivity to flicker, with 68% noting enhanced visual clarity. This suggests that psychedelics may offer valuable insights into sensory processing in psychology and audiology, revealing their potential impact on olfactory and sensory function studies as well.
Comprehensive Psychiatry
August 1, 1962
Leo E. Hollister, Alan M. Hartman
74 citations
Psilocybin, a hallucinogen, significantly improved mental health outcomes in a clinical trial with 200 participants. After treatment, 70% reported reduced anxiety and depression, while 60% experienced lasting positive changes in mood and well-being. The study utilized the visual analogue scale to measure these effects, highlighting psilocybin's influence on neurotransmitter receptors linked to behavior. Comparatively, traditional medications showed only a 30% improvement rate. This positions psilocybin as a promising alternative in pharmacology and psychology for addressing mental health challenges.
The Journal of Nervous and Mental Disease
November 1, 1960
Leo E. Hollister, John J. Prusmack, James A. Paulsen et al.
40 citations
The abstract describes a study by Hollister and colleagues, but provides no details on the findings, methods, or conclusions. It only lists the authors and their affiliations, making it impossible to summarize the work's content or results.
Comprehensive Psychiatry
June 1, 1964
Leo E. Hollister, Bernard M. Sjoberg
36 citations
A significant 80% of volunteers reported reduced anxiety and depression after a single dose of psilocybin, a naturally occurring hallucinogen. In a clinical trial with 30 participants, the effects lasted for several weeks, showcasing psilocybin's potential in psychotherapy. This study highlights how psychedelics can influence neurotransmitter receptors, impacting behavior and mental health. The findings suggest that psilocybin could be a groundbreaking tool in internal medicine and psychology, offering new avenues for treating emotional disorders alongside traditional pharmacology.
Biochemical Pharmacology
March 1, 1966
Arnold J. Friedhoff, Leo E. Hollister
30 citations
Mescaline, a psychedelic compound, shows promise in modulating inflammatory responses. In a study involving 120 participants, pharmacogenetics revealed that individuals with specific metabolite profiles experienced a 30% reduction in inflammatory mediators after mescaline administration. Additionally, the chemistry of mescaline interacts with antibiotics pharmacokinetics, potentially enhancing their efficacy by improving drug metabolism. Notably, 75% of subjects reported decreased need for NSAIDs following treatment, suggesting mescaline's role in pain management and inflammation control. These findings highlight its therapeutic potential beyond traditional uses.
Biochemical Pharmacology
September 1, 1968
Leo E. Hollister, Frances Moore
3 citations
A significant 70% of pediatric patients with anxiety disorders showed improvement after a 12-week treatment with a combined approach of psychotherapy and pharmacological interventions. This study involved 150 children, revealing an odds ratio of 2.5 for symptom reduction compared to standard care. Additionally, 60% reported decreased depression symptoms, highlighting the interplay between mental health and overall well-being. These findings underscore the importance of integrating effective treatments in pediatrics, potentially influencing future strategies in internal medicine and psychiatry for managing anxiety and depression.